Yes, ABPs have the potential to serve as cancer biomarkers. Their expression levels and mutation status can provide insights into cancer diagnosis and prognosis. For example, elevated levels of fascin, an ABP involved in bundling actin filaments, have been associated with poor prognosis in colorectal and breast cancer. Analyzing ABP expression can help in stratifying patients and tailoring personalized treatment strategies.
